Morgan Stanley trimmed its holdings in shares of Natera Inc (NASDAQ:NTRA) by 2.1% during the 3rd quarter, Holdings Channel reports. The firm owned 251,447 shares of the medical research company’s stock after selling 5,512 shares during the quarter. Morgan Stanley’s holdings in Natera were worth $6,020,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Pacer Advisors Inc. purchased a new stake in Natera during the 3rd quarter valued at $106,000. Point72 Hong Kong Ltd purchased a new stake in Natera during the 3rd quarter valued at $119,000. Quantbot Technologies LP purchased a new stake in Natera during the 3rd quarter valued at $135,000. Meeder Asset Management Inc. boosted its stake in Natera by 920.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock valued at $200,000 after purchasing an additional 7,576 shares during the last quarter. Finally, United Services Automobile Association purchased a new stake in Natera during the 3rd quarter valued at $214,000. Institutional investors and hedge funds own 87.92% of the company’s stock.
Several analysts have commented on the company. Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. BidaskClub downgraded Natera from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 13th. ValuEngine downgraded Natera from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 9th. Finally, Cowen reiterated a “buy” rating and set a $30.00 target price on shares of Natera in a research note on Friday, November 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Natera currently has a consensus rating of “Buy” and a consensus price target of $28.25.
NASDAQ NTRA opened at $16.17 on Thursday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 2.32 and a current ratio of 2.44. Natera Inc has a 1-year low of $8.60 and a 1-year high of $29.62.
TRADEMARK VIOLATION NOTICE: This story was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2019/02/21/natera-inc-ntra-holdings-reduced-by-morgan-stanley.html.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: The benefits and drawbacks of dollar cost averaging
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.